通气/灌注SPECT/CT在新冠后状态患者中的应用价值:一项多中心观察性研究
该回顾性多中心注册研究纳入217例新冠感染后持续呼吸道症状患者,在感染后平均26.7周±20周行V/Q SPECT/CT,由集中盲法阅片评估。结果显示仅6例(2.8%)存在提示肺栓塞的灌注不匹配缺损,95例(44.8%)V/Q SPECT/CT完全正常;作者认为V/Q SPECT/CT有助于鉴别器质性肺部异常与非器质性病因,PE虽少见但仍属需及时识别和治疗的严重并发症。
要点
- 217例新冠后持续呼吸道症状患者中,V/Q SPECT/CT示肺栓塞仅6例(2.8%),其中3例为既往未诊断的PE。
- 95例(44.8%)V/Q SPECT/CT完全正常,可有效排除器质性肺部受累。
- 非血栓栓塞性肺部异常116例(53.4%),CT异常107例(49.3%),以胸膜下和双侧为主。
核心结论
- V/Q SPECT/CT有助于在长新冠患者中鉴别器质性肺部异常与非器质性病因。
- 肺栓塞虽少见(2.8%),但仍是需要及时识别和治疗的严重并发症。
- 44.8%的患者V/Q SPECT/CT完全正常,可有效排除器质性肺部受累。
- 作者认为V/Q SPECT/CT等混合影像技术可考虑用于长新冠的诊断评估。
- 作者指出未来需要前瞻性研究来验证这些发现并探索肺部异常的长期临床意义。
研究设计与样本
- 回顾性、多中心研究,使用一个国家注册数据库纳入新冠感染后有症状患者行V/Q SPECT/CT检查。
- 采用集中、盲法阅片评估不匹配、匹配和反向不匹配缺损及肺部形态学异常。
- 共纳入217例持续呼吸道症状患者,感染至扫描平均时间26.7周±20周,评估时间为2020年1月至2023年4月。
- 采用描述性统计和比较分析评估肺栓塞及栓塞后遗症患病率。
- 次要目标为确定提示感染后遗症的影像学正常与异常表现的患病率。
主要发现
- 217例中6例(2.8%)存在提示肺栓塞的灌注不匹配缺损,包括3例既往未诊断的PE(1例新发、2例复发)。
- 72例有既往PE病史的患者中仅3例(4.2%)发现栓塞后遗症。
- 非血栓栓塞性肺部异常116例(53.4%),V/Q SPECT/CT完全正常95例(44.8%)。
- 匹配的通气-灌注缺损83例(38.2%),反向不匹配缺损13例(6.0%)。
- CT异常107例(49.3%),以胸膜下和双侧为主。
关键数值与推荐
- 肺栓塞定义为灌注不匹配缺损,217例中6例(2.8%)符合。
- 既往PE病史患者中栓塞后遗症为72例中3例(4.2%)。
- V/Q SPECT/CT完全正常者为95例(44.8%)。
- 匹配通气-灌注缺损83例(38.2%),反向不匹配缺损13例(6.0%)。
- CT异常107例(49.3%)。
临床怎么用
- 作者认为V/Q SPECT/CT可考虑作为长新冠诊断评估中有价值的工具。
- 作者指出V/Q SPECT/CT有助于鉴别器质性肺部异常与非器质性病因。
- 作者指出肺栓塞虽罕见但为需及时识别和治疗的严重并发症。
- 作者指出V/Q SPECT/CT完全正常可有效排除器质性肺部受累。
局限性
- 原文指出未来需要前瞻性研究来验证这些发现并探索肺部异常的长期临床意义。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The COVID-19 pandemic has led to a significant number of survivors experiencing persistent health issues, now recognized as long COVID. Respiratory symptoms, such as dyspnea, chronic cough, and reduced exercise capacity, are prevalent and can severely impact quality of life. Ventilation/Perfusion (V/Q) SPECT/CT is a hybrid imaging modality that offers both functional and anatomical insights and has proven valuable in evaluating pulmonary embolism (PE). However, its role in long COVID remains underexplored. METHODS: A retrospective, multicenter study was conducted using a national registry included V/Q SPECT/CT in symptomatic patients after COVID infection. Centralized, blinded reviews assessed for mismatched, matched, and reverse mismatch defects, as well as morphological lung abnormalities. Descriptive statistics and comparative analyses were performed to evaluate the prevalence of PE and post-embolic sequelae. A secondary objective is to determine the prevalence of normal versus abnormal imaging findings suggestive of post infectious sequelae. RESULTS: A total of 217 patients with persistent respiratory symptoms (mean time from infection to scan: 26.7 weeks ± 20 weeks) were evaluated between January 2020 and April 2023. Among the 217 patients, 6 (2.8%) exhibited mismatched perfusion defects consistent with PE, including 3 cases of previously undiagnosed PE (1 de novo and 2 recurrent). Post-embolic sequelae were identified in only 3 of 72 patients (4.2%) with a prior PE history. Non-thromboembolic lung abnormalities were found in 116 (53.4%) patients, while 95 (44.8%) had entirely normal V/Q SPECT/CT findings. Matched ventilation-perfusion defects were observed in 83 (38.2%) patients. Reverse mismatched defects were identified in 13 (6.0%) patients. CT abnormalities were present in 107 (49.3%) cases, predominantly subpleural and bilateral. CONCLUSION: V/Q SPECT/CT proved valuable in differentiating organic pulmonary abnormalities from non-organic causes in long COVID patients. While PE was rare (2.8%), it remains a serious complication requiring prompt identification and treatment. Notably, 44.8% of patients showed normal V/Q SPECT/CT findings, effectively ruling out organic pulmonary involvement. Hybrid imaging techniques, such as V/Q SPECT/CT, may be considered a valuable tool in the diagnostic assessment of long COVID. Future prospective studies are needed to validate these findings and explore the long-term clinical implications of pulmonary abnormalities in this population.
引用
- Bonnefoy PB, Pascal P, Ceyrat Q, et al. Interest of ventilation/perfusion SPECT/CT in patients with post-COVID condition: a multicenter observational study. Eur J Nucl Med Mol Imaging. 2025. PMID: 40457068. doi:10.1007/s00259-025-07374-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。